Contact Home Allon Therapeutics Inc Allon Logo

Allon Therapeutics Inc

© Copyright 2013
http://www.allontherapeutics.com/

  • Corporate
  • Research
  • Product Development
  • Investors
  • Healthcare Professionals
  • Patient Resources

THE TANGLES PATHWAY Discover how davunetide increases memory function

A STRONG FOUNDATION Find out why Allon’s clinical development strategy identifies opportunities

UPDATE FROM CEO Gordon McCauley

News

Allon Therapeutics releases first quarter 2013 operating results > April 29, 2013

Allon reports 2012 audited operating results > March 27, 2013

Allon provides shareholder update > February 5, 2013

Copyright 2013 Allon Therapeutics Inc. See legal terms for use of this site

  • Profile
  • Leadership
  • News
  • Careers

Allon Therapeutics Inc. is a clinical stage biotechnology company focused on commercializing high potential central nervous system drugs.

  • Science
  • Market
  • Indications
  • Research Publications

Allon’s focus is developing central nervous system therapies. Allon’s drug candidates have been shown to work at the cellular level to protect or shield neurons from injury.

  • Development Status
  • Davunetide
  • Preclinical
  • Partnering

Allon’s human clinical trials and animal studies show that davunetide reduces the neurodegenerative “tangles” pathology and also increases memory function.

  • Investment Highlights
  • News Releases
  • Shareholder Reports
  • Stock Quote
  • Analyst Coverage
  • Information Request

Allon’s lead drug davunetide, is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA.